Stock Comparison

LLY vs MYO

Eli Lilly and Co vs Myomo Inc

The Verdict

MYO takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

MYO

Myomo Inc

6.0

out of 10

Solid Pick

Head-to-Head

$965.0B

Market Cap

$54M

52.6

P/E Ratio

-3.8

N/A

Profit Margin

-36.7%

N/A

Return on Equity

-114.9%

N/A

Debt-to-Equity

1.0

Moderate

Overall Risk

Aggressive

0.5

DVR Score

6.0

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

MYO6.0/10

Myomo continues to address a large, underserved neurological rehabilitation market with its MyoPro device, validated by strong regulatory clearances and expanding reimbursement. Q1 2026 results, reported on May 9, 2026, exceeded consensus estimates with $10.1M revenue and narrower EPS loss of ($0.07), building on previous operational improvements. The formalization of Horton Capital's 6.0% stake a...

Full MYO Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.